Related Experiment Video
Updated: Jul 13, 2026

10:08
Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
Published on: August 28, 2012
Mapping the structural transition in an amyloidogenic apolipoprotein A-I
Jens O Lagerstedt1, Giorgio Cavigiolio, Linda M Roberts
1Department of Biochemistry and Molecular Medicine, University of California, Davis, California 95616, USA.
Biochemistry
|August 2, 2007
Summary
The Iowa mutation (G26R) in apolipoprotein A-I causes structural changes, leading to amyloid fibril formation and reduced lipid binding. This mutation promotes beta-sheet structures, driving protein aggregation.
Area of Science:
- Biochemistry
- Structural Biology
- Molecular Biology
Background:
- Human apolipoprotein A-I (apoA-I) is crucial for lipid metabolism.
- The Iowa mutation (G26R) in apoA-I is linked to amyloid fibril formation.
- Understanding the structural basis of apoA-I aggregation is vital for disease research.
Purpose of the Study:
- To investigate the molecular mechanisms by which the G26R mutation in apoA-I induces amyloid formation.
- To characterize the structural and functional changes associated with the apoA-IIOWA variant.
Main Methods:
- Electron paramagnetic resonance (EPR) spectroscopy to analyze protein structure.
- Electron microscopy to visualize protofibril formation.
- Lipid-binding assays and protease sensitivity experiments.
Main Results:
- The G26R mutation in apoA-I (apoA-IIOWA) decreases lipid-binding capability and increases protease sensitivity.
- The mutation promotes the formation of beta-secondary structures in regions 27-56.
- Electron microscopy revealed the formation of annular protofibrils, and amyloidophilic dyes indicated widespread aggregation in vitro.
Conclusions:
- The G26R mutation disrupts the native structure of apoA-I, promoting beta-strand formation and subsequent amyloid aggregation.
- Loss of Gly26's role in beta-strand termination and the introduction of Arg27 contribute to the proamyloidogenic nature of apoA-IIOWA.
- These structural alterations have significant functional consequences, including impaired lipid binding and aggregation into insoluble fibrils.
Related Concept Videos
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

